U S Physical Therapy Inc: Form 10-Q for the period ended Sep 30, 2018
Filed with the SEC on Nov 7, 2018 and accepted by EDGAR at Nov 7, 2018, 14:42 ET.
Management's discussion and analysis
As filed, 48,793 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with (i) our historical consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q; (ii) our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2018; and (iii) our management’s discussion and analysis of financial condition and results of operations included in our 2017 Form 10-K. This discussion includes forward-looking statements that are subject to risk and uncertainties. Actual results may differ substantially from the statements we make in this section due to a number of factors that are discussed in “Forward-Looking Statements” herein and “Part I – Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2017.
References to “we,” “us,” “our” and the “Company” shall mean U.S. Physical Therapy, Inc. and its subsidiaries.
EXECUTIVE SUMMARY
Our Business
We operate outpatient physical therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers and also operate an industrial injury prevention business. As of September 30, 2018, we operated 588 clinics in 42 states. We also manage physical therapy facilities for third parties, primarily hospital and physicians, with 26 third-party facilities under management as of September 30, 2018.
In March 2017, we acquired a 55% interest in a company which is a leading provider of industrial injury prevention services. The purchase price for the 55% interest was $6.2 million in cash and $0.4 million in a seller note that was paid, principal plus accrued interest, in September 2018. On April 30, 2018, we purchased a 65% interest in the assets and business of another industrial injury prevention services business, for an aggregate purchase price of $8.6 million in cash and $400,000 in seller note that is payable, plus accrued interest, on April 30, 2019. The two businesses were then combined. After the combination, the Company owns a 59.45% interest in the combined business.
During the first nine months of 2018 and the year ended 2017, we acquired the following clinic groups:
| Date | % Interest Acquired | Number of Clinics | |
|---|---|---|---|
| January 2017 Acquisition | January 1 | 70% | 17 |
| May 2017 Acquisition | May 31 | 70% | 4 |
| June 2017 Acquisition | June 30 | 60% | 9 |
| October 2017 Acquisition | October 31 | 70% | 9 |
| August 2018 Acquisition | August 31 | 70% | 4 |
On August 31, 2018 we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $7.3 million in cash and $400,000 in a seller note that is payable in two principal installments totaling $200,000 each, plus accrued interest, in August 2019 and August 2020.
In addition to the above, on February 28, 2018, through one of our majority owned Clinic Partnerships, we acquired two clinic practices for an aggregate purchase price of $760,000 and $150,000 in seller note that is payable, plus accrued interest, on August 31, 2019. These practices will operate as satellites of the existing Clinic Partnership.
On January 1, 2017, we acquired a 70% interest in a seventeen-clinic physical therapy practice. The purchase price for the 70% interest was $10.5 million in cash and $0.5 million in a seller note that was payable in two principal installments totaling $250,000 each, plus accrued interest. The first installment was paid in January 2018 and the second installment is due in January 2019.
On May 31, 2017, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $2.0 million in cash and $250,000 in a seller note that is payable in two principal installments totaling $125,000 each, plus accrued interest, the first was paid in May 2018 and the second installment is due in May 2019.
On June 30, 2017, we acquired a 60% interest in a nine-clinic physical therapy practice. The purchase price for the 60% interest was $15.8 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, the first was paid in June 2018 and the second is due in June 2019.
On October 31, 2017, we acquired a 70% interest in a nine-clinic physical therapy practice and two physical therapy management contracts with third party providers. The purchase price for the 70% interest was $3.0 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, the first was paid in October 2018 and the second installment is due in October 2019.
In addition to the clinic groups above, during the 2017 year, we purchased the assets and business of two physical therapy clinics in separate transactions. One clinic was consolidated with an existing clinic and the other operates as a satellite clinic of one of the existing partnerships.
Selected Operating and Financial Data
The following table presents selected operating and financial data that we believe are key indicators of our operating performance.
| For the Three Months Ended September 30, 2018 | September 30, 2017 | For the Nine Months Ended September 30, 2018 | September 30, 2017 | |
|---|---|---|---|---|
| Number of clinics, at the end of period | 588 | 569 | 588 | 569 |
| Working Days | 63 | 63 | 191 | 191 |
| Average visits per day per clinic | 26.6 | 25.6 | 26.4 | 25.5 |
| Total patient visits | 979,875 | 914,601 | 2,934,515 | 2,729,855 |
| Net patient revenue per visit | $105.48 | $105.26 | $105.60 | $105.35 |
RESULTS OF OPERATIONS
Three Months Ended September 30, 2018 Compared to the Three Months Ended September 30, 2017
- For the quarter ended September 30, 2018 (“2018 Third Quarter”), our Operating Results increased 34.9% to $8.1 million, or $.64 per diluted share, as compared to $6.0 million, or $.48 per diluted share, in the third quarter of 2017 (“2017 Third Quarter”). Operating Results, a non-generally accepted accounting principles (“non-GAAP”) measure, is defined below.
- For the 2018 Third Quarter, our net income attributable to our shareholders, in accordance with generally accepted accounting principles (“GAAP”), was $8.1 million as compared to $5.2 million for the 2017 Third Quarter. Earnings per diluted share of $0.13 in the 2018 Third Quarter compares to $0.41 per diluted share for the 2017 Third Quarter. For 2018, in accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, which is charged directly to retained earnings, is included in the earnings per basic and diluted share calculation. See the schedule below for a computation of diluted earnings per share and a reconciliation of net income attributable to our shareholders to Operating Results.
The following tables provide a detail of the basic and diluted earnings per share computation and reconcile net income attributable to our shareholders calculated in accordance with GAAP to Operating Results. We believe providing Operating Results to investors is useful information for comparing our period-to-period results.
For 2018, Operating Results equal net income attributable to our shareholders. Also for 2018, in accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, charged directly to retained earnings is included in the earnings per basic and diluted share calculation. For 2017, Operating Results, was defined as net income attributable to common shareholders prior to charge for interest expense – mandatorily redeemable non-controlling interests – change in redemption value and charge for cost related to restatement of financials – legal and accounting, both charges net of tax. Operating Results for the two periods are comparable, however, the calculations differ. Management uses Operating Results, which eliminates this current non-cash item that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance period over period. Management believes that Operating Results is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have mandatorily redeemable instruments and therefore have different liability and equity structures.
| Computation of earnings per share - USPH shareholders | Three Months Ended September 30, 2018 | 2017 |
|---|---|---|
| Net income attributable to USPH shareholders | $8,102 | $5,150 |
| Charges to retained earnings: | ||
| Revaluation of redeemable non-controlling interest | $(8,680) | $- |
| Tax effect at statutory rate (federal and state) of 26.25% | 2,279 | - |
| $1,701 | $5,150 | |
| Basic and diluted per share | $0.13 | $0.41 |
| Adjustments: | ||
| Interest expense MRNCI * - change in redemption value | - | 1,247 |
| Cost related to restatement of financials - legal and accounting | - | 158 |
| Revaluation of redeemable non-controlling interest | 8,680 | - |
| Tax effect at statutory rate (federal and state) of 26.25% and 39.25%, respectively | (2,279) | (551) |
| Operating results | $8,102 | $6,004 |
| Basic and diluted operating results per share | $0.64 | $0.48 |
| Shares used in computation: | ||
| Basic and diluted | 12,685 | 12,581 |
* Mandatorily redeemable non-controlling interest
Revenues
- Net revenues increased $10.1 million or 9.8% from $103.0 million in the 2017 Third Quarter to $113.1 million in 2018 Third Quarter, primarily due to an increase in net patient revenues from physical therapy operations from both internal growth and acquisitions, an increase in revenue from physical therapy management contracts primarily due to acquired contracts and an increase in the revenue from the industrial injury prevention business from a combination of internal growth plus a recent acquisition. Our first company in the industrial injury prevention business was acquired in March 2017 and, on April 30, 2018, the Company made a second acquisition, with the two businesses then combined. See above discussion under “Executive Summary”.
- Net patient revenues from physical therapy operations increased approximately $7.1 million, or 7.4%, to $103.4 million in the 2018 Third Quarter from $96.3 million in the 2017 Third Quarter due to an increase in total patient visits of 7.1% from 915,000 to 980,000 and an increase in the average net patient revenue per visit to $105.48 from $105.26. Of the $7.1 million increase, $4.2 million in net patient revenues related to an increase in business of clinics opened or acquired on or prior to September 30, 2017 (“Mature Clinics”) and $2.9 million related to clinics opened or acquired after September 30, 2017 (“New Clinics”). Revenue from physical therapy management contracts increased 12.9% to $1.9 million in the 2018 Third Quarter as compared to $1.7 million for the 2017 Third Quarter.
- The revenue from the industrial injury prevention business increased 66.8% to $7.3 million for the 2018 Third Quarter compared to $4.4 million in the 2017 Third Quarter primarily due to internal growth ($1.3 million) and the acquisition on April 30, 2018 ($1.7 million). Other revenue was $0.6 million in the 2018 Third Quarter and $0.7 million in 2017 Third Quarter.
Net patient revenues are based on established billing rates less allowances for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under contractual programs and workers’ compensation are based on predetermined rates and are generally less than the established billing rates.
Operating Costs
Total operating costs were $87.0 million, or 76.9% of net revenues, in the 2018 Third Quarter as compared to $81.8 million, or 79.4% of net revenues, in the 2017 Third Quarter. The $5.2 million increase was attributable to $3.7 million in operating costs related to New Clinics, and a decrease of $0.1 million related to Mature Clinics, an increase of $1.4 million in the industrial injury prevention business primarily due to the most recent acquisition and an increase of $0.2 million related to physical therapy management contracts. Each component of operating costs is discussed below:
Operating Costs—Salaries and Related Costs
Salaries and related costs increased to $64.5 million for the 2018 Third Quarter from $60.3 million for the 2017 Third Quarter, an increase of $4.2 million. Salaries and related costs for New Clinics amounted to $1.8 million for the 2018 Third Quarter. Salaries and related costs for the industrial injury prevention business was $4.2 million in the 2018 Third Quarter compared to $3.0 million 2017 Third Quarter, an increase of $1.2 million primarily due to the recent acquisition. For Mature Clinics, salaries and related costs decreased by $0.4 million for the 2018 Third Quarter compared to the 2017 Third Quarter. For physical therapy physical therapy management contracts, salaries and related costs increased by $1.6 million, of which $1.4 million related to new contracts, for the 2018 Third Quarter compared to the 2017 Third Quarter. Salaries and related costs as a percentage of net revenues were 57.0% for the 2018 Third Quarter and 58.5% for the 2017 Third Quarter.
Operating Costs—Rent, Supplies, Contract Labor and Other
Rent, supplies, contract labor and other were $21.7 million for the 2018 Third Quarter and $20.6 million for the 2017 Third Quarter. For New Clinics, rent, supplies, contract labor and other amounted to $1.1 million for the 2018 Third Quarter. Rent, supplies, contract labor and other for the industrial injury prevention business increased by $0.2 million in the 2018 Third Quarter compared to the 2017 Third Quarter primarily due to the recent acquisition. For Mature Clinics, rent, supplies, contract labor and other increased by $0.2 million in the 2018 Third Quarter. For physical therapy management contracts, rent, supplies, contract labor and other decreased by $0.4 million in the 2018 Third Quarter. Rent, supplies, contract labor and other as a percentage of net revenues was 19.1% for the 2018 Third Quarter and 20.0% for the 2017 Third Quarter.
Operating Costs—Provision for Doubtful Accounts
The provision for doubtful accounts was $0.9 million for both the 2018 and the 2017 Third Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 0.8% for the 2018 Third Quarter and 0.9% for the 2017 Third Quarter.
Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.8% at September 30, 2018, as compared to 4.9% at December 31, 2017. Our day’s sales outstanding were 38 days at September 30, 2018 and 36 days at December 31, 2017.
Gross Profit
The gross profit for the 2018 Third Quarter grew by 23.0% or $4.9 million to $26.1 million, as compared to $21.2 million in the 2017 Third Quarter. The gross profit percentage was 23.1% of net revenue in the most recent period as compared to 20.6% in the 2017 Third Quarter. The gross profit percentage for our physical therapy clinics was 22.8% in the recent quarter as compared to 20.9% in the 2017 Third Quarter. The gross profit percentage on physical therapy management contracts was 9.9% in the 2018 Third Quarter as compared to 16.8% in the 2017 Third Quarter. The gross profit percentage for the industrial injury prevention business was 29.7% in the recent quarter as compared to 14.1% in the 2017 Third Quarter.
Corporate Office Costs
Corporate office costs, consisting primarily of salaries, incentive compensation, and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $10.6 million for the 2018 Third Quarter and $8.3 million for the 2017 Third Quarter. As a percentage of net revenues, corporate office costs were 9.4% for the 2018 Third Quarter and 8.1% for the 2017 Third Quarter.
Interest Expense mandatorily redeemable non-controlling interest – change in redemption value and earnings allocable
The Company no longer has mandatorily redeemable non-controlling interests. As previously mentioned, due to amended partnerships agreements, the redemption values of the mandatorily redeemable non-controlling interests (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) at fair value on the December 31, 2017 consolidated balance sheet. For 2017, the earnings and liabilities attributable to mandatorily redeemable non-controlling interests were recorded within the consolidated statements of income line item: Interest expense – mandatorily redeemable non-controlling interests – earnings allocable and in the consolidated balance sheet line item: Mandatorily redeemable non-controlling interests. For 2018, any adjustments in the redemption value, net of tax, are recorded directly to retained earnings and are not reflected in the consolidated statements of income. Although the redemption adjustments are not reflected in the consolidated statements of income, current accounting rules require that the Company reflects these adjustments, net of tax, in the earnings per share calculation.
Interest Expense mandatorily redeemable non-controlling interest – change in redemption value for the 2017 Third Quarter was $1.2 million. The change in redemption value for acquired partnerships was based on the redemption amount (which is derived from a formula based on a specified multiple times the underlying business’ trailing twelve months of earnings before interest, taxes, depreciation, amortization and our internal management fee) at the end of the reporting period compared to the end of the previous period. This change is directly related to an increase or decrease in the profitability and underlying value of the Company’s partnerships as compared to the prior quarter.
For 2018, the amount of net income attributable to redeemable non-controlling interest owners is included in consolidated net income on the face of the consolidated statement of income in the line item – Net income attributable to non-controlling interests. For 2017, interest expense – mandatorily redeemable non-controlling interest – earnings allocable, which represent the portion of earnings allocable to the holders of mandatorily redeemable non-controlling interests, was $1.3 million in 2017 Third Quarter.
Interest Expense – debt and other
Interest expense decreased to $580,000 in the 2018 Third Quarter compared to $641,000 in the 2017 Third Quarter. At September 30, 2018, $54.0 million was outstanding under our Amended Credit Agreement. See “—Liquidity and Capital Resources” below for a discussion of the terms of our Amended Credit Agreement.
Provision for Income Taxes
The provision for income taxes for the 2018 Third Quarter was $3.0 million and for the 2017 Third Quarter was $3.1 million. The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest was 27.0% and 37.8%, respectively, for the 2018 Third Quarter and 2017 Third Quarter.
Non-controlling Interests
Net income attributable to non-controlling interests (permanent equity) was $1.3 million for both the 2018 and 2017 Third Quarters. Net income attributable to redeemable non-controlling interests (temporary equity) was $2.5 million in the 2018 Third Quarter. See discussion above.
Nine Months Ended September 30, 2018 Compared to the Nine Months Ended September 30, 2017
- For the nine months ended September 30, 2018 (“2018 First Nine Months”), our Operating Results increased 22.6% to $24.5 million, or $1.93 per diluted share, as compared to $20.0 million, or $1.59 per diluted share, in the first nine months of 2017 (“2017 First Nine Months”). Operating Results, a non-GAAP measure, is defined below.
- For the 2018 First Nine Months, our net income attributable to our shareholders, in accordance with generally accepted accounting principles (“GAAP”), was $24.5 million as compared to $14.9 million for the 2017 period. Earnings per diluted share of $0.88 in the 2018 First Nine Months compares to $1.19 per diluted share for the 2017 First Nine Months. For 2018, in accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, which is charged directly to retained earnings is included in the earnings per basic and diluted share calculation. See the schedule below for a computation of basic and diluted earnings per share and a reconciliation of net income attributable to our shareholders to Operating Results.
The following tables provide a detail of the basic and diluted earnings per share computation and reconcile net income attributable to our shareholders calculated in accordance with GAAP to Operating Results. We believe providing Operating Results to investors is useful information for comparing our period-to-period results.
For 2018, Operating Results equal net income attributable to our shareholders and, in accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, charged directly to retained earnings is included in the earnings per basic and diluted share calculation. For 2017, Operating Results were defined as net income attributable to common shareholders prior to charge for interest expense – mandatorily redeemable non-controlling interests – change in redemption value and charge for cost related to restatement of financials – legal and accounting, both charges net of tax. Operating Results for the two periods are comparable, however, the calculations differ. Management uses Operating Results, which eliminates this current non-cash item that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance period over period. Management believes that Operating Results is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have mandatorily redeemable instruments and therefore have different liability and equity structures.
| Computation of earnings per share - USPH shareholders | Nine Months Ended September 30, 2018 | 2017 |
|---|---|---|
| Net income attributable to USPH shareholders | $24,465 | $14,907 |
| Charges to retained earnings: | ||
| Revaluation of redeemable non-controlling interest | (18,105) | - |
| Tax effect at statutory rate (federal and state) of 26.25% | 4,753 | - |
| $11,113 | $14,907 | |
| Basic and diluted per share | $0.88 | $1.19 |
| Adjustments: | ||
| Interest expense MRNCI * - change in redemption value | - | 7,839 |
| Cost related to restatement of financials - legal and accounting | - | 470 |
| Revaluation of redeemable non-controlling interest | 18,105 | - |
| Tax effect at statutory rate (federal and state) of 26.25% and 39.25%, respectively | (4,753) | (3,261) |
| Operating results | $24,465 | $19,955 |
| Basic and diluted operating results per share | $1.93 | $1.59 |
| Shares used in computation: | ||
| Basic and diluted | 12,660 | 12,563 |
Revenues
- Net revenues increased $31.7 million or 10.4% from $304.8 million in the 2017 First Nine Months to $336.5 million in the 2018 First Nine Months, primarily due to an increase in net patient revenues from physical therapy operations from both internal growth and acquisitions, an increase in revenue from physical therapy management contracts due to acquired contracts and an increase in the revenue from the industrial injury prevention business from a combination of internal growth plus a recent acquisition and due to a full nine months of activity in 2018 for the business acquired in March 2017. Our first company in the industrial injury prevention business was acquired in March 2017 and, on April 30, 2018, the Company made a second acquisition with the two businesses then combined. See above discussion under “Executive Summary”.
- Net patient revenues from physical therapy operations increased approximately $22.3 million, or 7.8%, to $309.9 million in the 2018 First Nine Months from $287.6 million in the 2017 First Nine Months due to an increase in total patient visits of 7.5% from 2,730,000 to 2,935,000 and an increase in the average net patient revenue per visit to $105.60 from $105.35. Of the $22.3 million increase, $12.7 million related to Mature Clinics and $9.6 million related to New Clinics. Revenue from physical therapy management contracts increased 22.1% to $6.3 million in the 2018 First Nine Months as compared to $5.1 million for the 2017 First Nine Months.
- The revenue from the industrial injury prevention business was $18.4 million for the 2018 First Nine Months as compared to $10.2 million in the 2017 First Nine Months due to internal growth and the recent acquisition. Other revenue was $2.0 million in the 2018 First Nine Months and $1.8 million in the 2017 First Nine Months.
Net patient revenues are based on established billing rates less allowances for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under contractual programs and workers’ compensation are based on predetermined rates and are generally less than the established billing rates.
Operating Costs
Total operating costs were $260.1 million, or 77.3% of net revenues, in the 2018 First Nine Months as compared to $238.4 million, or 78.2% of net revenues, in the 2017 First Nine Months. The $21.7 million increase was attributable to $8.8 million in operating costs related to New Clinics, an increase of $5.4 million related to Mature Clinics, an increase of $5.2 million related to the industrial injury prevention business primarily due to the most recent acquisition and a full nine months of activity in 2018 for the business acquired in March 2017 versus four months in 2017 and an increase of $2.3 million related to physical therapy management contracts. Each component of operating costs is discussed below:
Operating Costs—Salaries and Related Costs
Salaries and related costs increased to $191.4 million for the 2018 First Nine Months from $174.9 million for the 2017 First Nine Months, an increase of $16.5 million. Salaries and related costs for New Clinics amounted to $6.1 million for the 2018 First Nine Months. Salaries and related costs for the industrial injury prevention business increased by $4.2 million in the 2018 First Nine Months compared to the 2017 First Nine Months due to the recent acquisition and nine months of activity in the 2018 period versus four months in the 2017 period. See above discussion under “Executive Summary” related to the acquisition and combining of the industrial injury prevention business. For Mature Clinics, salaries and related costs increased by $4.1 million for the 2018 First Nine Months compared to the 2017 First Nine Months. For physical therapy management contracts, salaries and related costs increased by $2.1 million for the 2018 First Nine Months compared to the 2017 First Nine Months. Salaries and related costs as a percentage of net revenues were 56.9% for the 2018 First Nine Months and 57.4% for the 2017 period.
Operating Costs—Rent, Supplies, Contract Labor and Other
Rent, supplies, contract labor and other were $65.6 million for the 2018 First Nine Months and $60.7 million for the 2017 First Nine Months. For New Clinics, rent, supplies, contract labor and other amounted to $2.7 million for the 2018 First Nine Months. Rent, supplies, contract labor and other for the industrial injury prevention business increased by $1.0 million in the 2018 First Nine Months compared to the 2017 First Nine Months due to the recent acquisition and nine months of activity in the 2018 period versus four months in the 2017 period. See above discussion under “Executive Summary” related to the acquisition and combining of the industrial injury prevention business. For Mature Clinics, rent, supplies, contract labor and other increased by $1.6 million in the 2018 First Nine Months. For physical therapy management contracts, rent, supplies, contract labor and other decreased by $0.4 million in the 2018 First Nine Months. Rent, supplies, contract labor and other as a percentage of net revenues was 19.5% for the 2018 First Nine Months and 19.9% for the 2017 First Nine Months.
Operating Costs—Provision for Doubtful Accounts
The provision for doubtful accounts was $3.1 million for the 2018 First Nine Months and $2.7 million for the 2017 First Nine Months. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was approximately 1.0% for both the 2018 First Nine Months and the 2017 First Nine Months.
Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.8% at September 30, 2018, as compared to 4.9% at December 31, 2017. Our day’s sales outstanding were 38 days at September 30, 2018 and 36 days at December 31, 2017.
Gross Profit
The gross profit for the 2018 First Nine Months grew by 15.0% or $10.0 million to $76.4 million, as compared to $66.4 million in the 2017 First Nine Months. The gross profit percentage was 22.7% of net revenue in the most recent period as compared to 21.8% for the 2017 First Nine Months. The gross profit percentage for our physical therapy clinics was 22.6% in the 2018 First Nine Months as compared to 22.2% in the 2017 First Nine Months. The gross profit percentage on physical therapy management contracts was 22.0% in the 2018 First Nine Months as compared to 13.1% in the 2017 First Nine Months. The gross profit percentage for the industrial injury prevention business was 24.2% for the 2018 First Nine Months as compared to 14.5% for the four months of operation in the 2017 period.
Corporate Office Costs
Corporate office costs, consisting primarily of salaries, incentive compensation, and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $30.9 million for the 2018 Third Quarter and $25.7 million for the 2017 First Nine Months. As a percentage of net revenues, corporate office costs were 9.2% for the 2018 First Nine Months and 8.4% for the 2017 First Nine Months.
Interest Expense mandatorily redeemable non-controlling interest – change in redemption value and earnings allocable
The Company no longer has mandatorily redeemable non-controlling interests. As previously mentioned, due to amended partnerships agreements, the redemption values of the mandatorily redeemable non-controlling interests (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) at fair value on the December 31, 2017 consolidated balance sheet. For 2017, the earnings and liabilities attributable to mandatorily redeemable non-controlling interests were recorded within the consolidated statements of income line item: Interest expense – mandatorily redeemable non-controlling interests – earnings allocable and in the consolidated balance sheet line item: Mandatorily redeemable non-controlling interests. For 2018, any adjustments in the redemption value, net of tax, are recorded directly to retained earnings and are not reflected in the consolidated statements of income. Although the redemption adjustments are not reflected in the consolidated statements of income, current accounting rules require that the Company reflects these adjustments, net of tax, in the earnings per share calculation.
Interest Expense mandatorily redeemable non-controlling interest – change in redemption value for the 2017 First Nine Months was $7.8 million. The change in redemption value for acquired partnerships was based on the redemption amount (which is derived from a formula based on a specified multiple times the underlying business’ trailing twelve months of earnings before interest, taxes, depreciation, amortization and our internal management fee) at the end of the reporting period compared to the end of the previous period. This change is directly related to an increase or decrease in the profitability and underlying value of the Company’s partnerships as compared to the prior quarter.
For 2018, the amount of net income attributable to redeemable non-controlling interest owners is included in consolidated net income on the face of the consolidated statement of income in the line item – Net income attributable to non-controlling interests. For 2017, interest expense – mandatorily redeemable non-controlling interest – earnings allocable, which represent the portion of earnings allocable to the holders of mandatorily redeemable non-controlling interests, was $4.4 million in 2017 First Nine Months.
Interest Expense – debt and other
Interest expense increased to $1.7 million in the 2018 First Nine Months compared to $1.6 million in the 2017 First Nine Months due to a higher average effective interest rate, inclusive of unused fees, outstanding under our Amended Credit Agreement. At September 30, 2018, $54.0 million was outstanding under our Amended Credit Agreement. See “—Liquidity and Capital Resources” below for a discussion of the terms of our Amended Credit Agreement.
Provision for Income Taxes
The provision for income taxes for the 2018 First Nine Months was $8.7 million and for the 2017 First Nine Months was $8.0 million both inclusive of the reduction of $0.7 million and $1.1 million, respectively, for the excess tax benefit, which is a component of the provision for income taxes, related to equity compensation. The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest was 26.3% and 35.0%, respectively, for the 2018 First Nine Months and 2017 First Nine Months.
Non-controlling Interests
Net income attributable to non-controlling interests (permanent equity) was $3.9 million for the 2018 First Nine Months and $4.1 million for the 2017 First Nine Months. Net income attributable to redeemable non-controlling interests (temporary equity) was $6.8 million in the 2018 First Nine Months. See discussion above.
LIQUIDITY AND CAPITAL RESOURCES
We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At September 30, 2018 and December 31, 2017, we had $32.2 million and $21.9 million, respectively, in cash. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our revolving credit agreement are sufficient to fund the working capital needs of our operating subsidiaries, future clinic development and acquisitions and investments through at least September 2019. Significant acquisitions would likely require additional financing.
Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility. This agreement was amended in August 2015, January 2016, March 2017 and November 2017 (hereafter referred to as “Amended Credit Agreement”). The Amended Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Amended Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common stockholders, capital expenditures and other corporate purposes. The pricing grid is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.25% to 2.0% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Amended Credit Agreement include an unused commitment fee ranging from 0.25% to 0.3% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Amended Credit Agreement.
The January 2016 amendment to the Amended Credit Agreement increased the cash and noncash consideration that we could pay with respect to acquisitions permitted under the Amended Credit Agreement to $50,000,000 for any fiscal year, and increased the amount we may pay in cash dividends to our shareholders in an aggregate amount not to exceed $10,000,000 in any fiscal year. The March 2017 amendment, among other items, increased the amount we may pay in cash dividends to our shareholders in an aggregate amount not to exceed $15,000,000 in any fiscal year. The November 2017 amendment, among other items, adjusted the pricing grid as described above, increased the aggregate amount we may pay in cash dividends to $20,000,000 to our shareholders and extended the maturity date to November 30, 2021.
Cash and cash equivalents increased by $10.3 million from December 31, 2017 to September 30, 2018. During the nine months ended September 30, 2018, $54.0 million was provided by operations. The major uses of cash for investing and financing activities included: purchase of businesses ($16.3 million), distributions to non-controlling interests inclusive of those classified as redeemable non-controlling interests ($10.5 million), cash dividend paid to shareholders ($8.7 million), purchases of fixed assets ($5.3 million), payments on notes payable ($2.3 million), purchases of non-controlling interests ($0.3 million), and payments to settle mandatorily redeemable non-controlling interests ($0.3 million).
On February 28, 2018, through one of our majority owned partnerships, we acquired the assets and business of two physical therapy clinics, for an aggregate purchase price of $760,000 in cash and $150,000 in seller note that is payable, plus accrued interest, on August 31, 2019.
On April 30, 2018, we purchased a 65% interest in the assets and business of industrial injury prevention services, for an aggregate purchase price of $8.6 million in cash and $400,000 in seller note that is payable, plus accrued interest, on April 30, 2019. The initial industrial injury prevention business was acquired in March 2017 and, on April 30, 2018, we made a second acquisition with the two businesses then combined. After the combination, we own a 59.45% interest in the combined business.
On August 31, 2018 we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $7.3 million in cash and $400,000 in a seller note that is payable in two principal installments totaling $200,000 each, plus accrued interest, in August 2019 and August 2020.
On January 1, 2017, we acquired a 70% interest in a seventeen-clinic physical therapy practice. The purchase price for the 70% interest was $10.7 million in cash and $0.5 million in a seller note that was payable in two principal installments totaling $250,000 each, plus accrued interest. The first installment was paid in January 2018 and the second installment is due in January 2019.
On May 31, 2017, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $2.3 million in cash and $250,000 in a seller note that is payable in two principal installments totaling $125,000 each, plus accrued interest. The first installment was paid in May 2018 and the second installment is due May 2019.
On June 30, 2017, we acquired a 60% interest in a nine-clinic physical therapy practice. The purchase price for the 60% interest was $15.8 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest. The first installment was paid in June 2018 and the second installment is due June 2019.
On October 31, 2017, we acquired a 70% interest in a nine-clinic physical therapy practice and two physical therapy management contracts with third party providers. The purchase price for the 70% interest was $4.0 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in October 2018 and 2019.
Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.
We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for nine months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.
We generally enter into various notes payable as a means of financing our acquisitions. Our outstanding notes payable as of September 30, 2018 relate to certain of the acquisitions of businesses, purchases of non-controlling interests and settlements of mandatorily redeemable non-controlling interests that occurred in 2015 through September 2018. Typically, the notes are payable in equal annual installments of principal over two years plus any accrued and unpaid interest. Interest accrues at various interest rates ranging from 3.25% to 5.0% per annum, subject to adjustment. At September 30, 2018, the balance on these notes payable was $5.4 million. In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities.
In conjunction with the above mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after a specified date that is typically between three and five years from the acquisition date, we have agreed to certain contractual provisions which enable such minority partners to exercise its right to trigger our repurchase of that partner’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.
As of September 30, 2018, we have accrued $6.7 million related to credit balances due to patients and payors. This amount is expected to be paid in the next twelve months.
From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). Our Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with covenants. We are required to retire shares purchased under the March 2009 Authorization.
There is no expiration date for the share repurchase program. As of September 30, 2018, there are currently an additional estimated 126,475 shares (based on the closing price of $118.60 on September 30, 2018) that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the nine months ended September 30, 2018.
FACTORS AFFECTING FUTURE RESULTS
The risks related to our business and operations include:
- changes as the result of government enacted national healthcare reform;
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
- revenue and earnings expectations;
- legal actions, which could subject us to increased operating costs and uninsured liabilities;
- general economic conditions;
- availability and cost of qualified physical therapists;
- personnel productivity and retaining key personnel;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
- maintaining our information technology systems with adequate safeguards to protect against cyber attacks;
- maintaining adequate internal controls;
- maintaining necessary insurance coverage;
- availability, terms, and use of capital; and
- weather and other seasonal factors.
See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 30, 2017.
Forward-Looking Statements
We make statements in this report that are considered to be forward-looking statements within the meaning given such term under Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to the risks listed above.
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see the other sections of this report and our other periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement may no longer be accurate.
Market risk
As filed, 591 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Amended Credit Agreement. The interest on our Amended Credit Agreement is based on a variable rate. At September 30, 2018, $54.0 million was outstanding under our Amended Credit Agreement. Based on the balance of the Amended Credit Agreement at September 30, 2018, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $540,000.
Controls and procedures
As filed, 1,386 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.
(b) Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-07-01 to 2018-09-30 | $113.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2018-01-01 to 2018-09-30 | $336.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months2018-07-01 to 2018-09-30 | $26.1m | us-gaap:GrossProfit |
| Gross profit | 9 months2018-01-01 to 2018-09-30 | $76.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2018-07-01 to 2018-09-30 | $10.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2018-01-01 to 2018-09-30 | $30.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2018-07-01 to 2018-09-30 | $15.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-01-01 to 2018-09-30 | $45.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-07-01 to 2018-09-30 | $579.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2018-01-01 to 2018-09-30 | $1.7m | us-gaap:InterestExpense |
| Income tax | 3 months2018-07-01 to 2018-09-30 | $3.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2018-01-01 to 2018-09-30 | $8.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-07-01 to 2018-09-30 | $8.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2018-01-01 to 2018-09-30 | $24.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-07-01 to 2018-09-30 | $0.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2018-01-01 to 2018-09-30 | $0.88 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2018-01-01 to 2018-09-30 | $54.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2018-01-01 to 2018-09-30 | $5.3m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months2018-01-01 to 2018-09-30 | $8.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2018-09-30 | $32.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-09-30 | $90.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $455.0m | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $47.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-09-30 | $113.0m | us-gaap:Liabilities |
| Long-term debt | At period end2018-09-30 | $54.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2018-09-30 | $4.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2018-09-30 | $211.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140361-18-042626. Last ingested by Listed: Nov 14, 2026, 13:45 ET. Listed shows no prices and gives no investment advice.